Agus Ahadi Deradjat
Mr. Agus Ahadi Deradjat joined ABNR in November 1996 and has been a key partner of the firm since 2004. A 1996 graduate of the University of Indonesia’s Faculty of Law, where he majored in business law, he focuses his practice on Corporate/M&A, Regulatory, FDI, and TMT. He has particular expertise in the Pharmaceuticals & Life Sciences sector, and counts among his clients many of the largest multinational and domestic companies in the pharma, medical devices and diagnostics industries, whom he advises on such aspects as M&A, FDI, licensing & regulatory, product liability, halal compliance, and dispute resolution. He also …
Mr. Agus Ahadi Deradjat joined ABNR in November 1996 and has been a key partner of the firm since 2004. A 1996 graduate of the University of Indonesia’s Faculty of Law, where he majored in business law, he focuses his practice on Corporate/M&A, Regulatory, FDI, and TMT.
He has particular expertise in the Pharmaceuticals & Life Sciences sector, and counts among his clients many of the largest multinational and domestic companies in the pharma, medical devices and diagnostics industries, whom he advises on such aspects as M&A, FDI, licensing & regulatory, product liability, halal compliance, and dispute resolution. He also regularly advises clients in the food sector.
Outside Pharma & Life Sciences, Agus has a very significant TMT practice, providing Indonesian legal advice to a long list of leading international names in this practice area, including some of the world’s largest technology and internet companies.
In other work, he recently concluded South Korea-based Samtan’s USD 517.5-million acquisition of Kideco Jaya Agung (which unexpectedly had to be restructured following the imposition of additional conditions by the Indonesian Government in 2018). In 2017/2018, he was joint head of the ABNR team that handled Henkel’s acquisition of PT CGP Applied Technologies Indonesia as part of Henkel’s global acquisition of GCP Applied technologies Inc. In the same year, he also successfully saw through Indonesian unicorn Traveloka’s USD-68 million acquisition of online travel agencies in Indonesia, Vietnam and the Philippines.
He was recently recognized once again as one of Indonesia’s top-100 lawyers by Vantage Asia / Asia Business Law Journal.
EMAIL:
aderadjat@abnrlaw.com
See more
He has particular expertise in the Pharmaceuticals & Life Sciences sector, and counts among his clients many of the largest multinational and domestic companies in the pharma, medical devices and diagnostics industries, whom he advises on such aspects as M&A, FDI, licensing & regulatory, product liability, halal compliance, and dispute resolution. He also regularly advises clients in the food sector.
Outside Pharma & Life Sciences, Agus has a very significant TMT practice, providing Indonesian legal advice to a long list of leading international names in this practice area, including some of the world’s largest technology and internet companies.
In other work, he recently concluded South Korea-based Samtan’s USD 517.5-million acquisition of Kideco Jaya Agung (which unexpectedly had to be restructured following the imposition of additional conditions by the Indonesian Government in 2018). In 2017/2018, he was joint head of the ABNR team that handled Henkel’s acquisition of PT CGP Applied Technologies Indonesia as part of Henkel’s global acquisition of GCP Applied technologies Inc. In the same year, he also successfully saw through Indonesian unicorn Traveloka’s USD-68 million acquisition of online travel agencies in Indonesia, Vietnam and the Philippines.
He was recently recognized once again as one of Indonesia’s top-100 lawyers by Vantage Asia / Asia Business Law Journal.
EMAIL:
aderadjat@abnrlaw.com
